Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: A report from the children's oncology group

Blood

Volumn 111, Issue 5, 2008, Pages 2548-2555

  Seibel, Nita L ^a,p   Steinherz, Peter G ^b   Sather, Harland N ^c   Nachman, James B ^d   Delaat, Cynthia ^e   Ettinger, Lawrence J ^f   Freyer, David R ^g   Mattano Jr , Leonard A ^h   Hastings, Caroline A ⁱ   Rubin, Charles M ^d   Bertolone, Kathy ^j   Franklin, Janet L ^k   Heerema, Nyla A ^l   Mitchell, Torrey L ^m   Pyesmany, Allan F ⁿ   La, Mei K ^c   Edens, Cheryl ^o   Gaynon, Paul S ^k  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c CHILDREN S ONCOLOGY GROUP   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^f SAINT PETER S UNIVERSITY HOSPITAL   (United States)

^g HELEN DEVOS CHILDREN S HOSPITAL   (United States)

^h Kalamazoo Center for Medical Studies   (United States)

ⁱ Children's Hospital   (United States)

^j KOSAIR CHILDREN'S HOSPITAL   (United States)

^k CHILDREN S HOSPITAL LOS ANGELES   (United States)

^l THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^m Blank Children's Hospital   (United States)

ⁿ IWK HEALTH CENTRE   (Canada)

^o VANDERBILT UNIVERSITY   (United States)

^p CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; ASPARAGINASE MACROGOL; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; TIOGUANINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; DISEASE FREE SURVIVAL; FOLLOW UP; LYMPHATIC LEUKEMIA; MORTALITY; REMISSION; RISK FACTOR; SURVIVAL RATE; TIME; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REMISSION INDUCTION; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 41949098006     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-02-070342     Document Type: Article

References (13)

1. Henze G, Langermann HJ, Bramswig J, et al. The BFM 76/79 acute lymphoblastic leukemia therapy study. Klin Padiatr. 1981;193:145-154.
2. Tubergen DG, Gilchrist GS, O'Brien RT, et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial. J Clin Oncol. 1993; 11:527-537.
3. Lange BJ, Bostrom BC, Cherlow JM, et al. Double-delayed intensification improves event free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 2002;99:825-833.
4. Nachman JB, Sather HN, Sensel MG, et al. Augmented postinduction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338:1663-1671.
5. Uckun F, Reaman G, Steinherz PG, et al. Improved clinical outcome for children with T- lineage acute lymphoblastic leukemia after contemporary chemotherapy: a Children's Cancer Group Study. Leuk Lymphoma. 1996;24:57-70.
6. Mattano LA Jr, Sather HN, Trigg ME, Nachman JB. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group. J Clin Oncol. 2000;18:3262-3272.
7. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
8. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer. 1977;35:1-39.
9. Breslow N. Analysis of survival data under the proportional hazards model. Int Stat Rev. 1975; 43:45-58.
10. Nachman J, Sather HN, Cherlow JM, et al. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group. J Clin Oncol. 1998;16:920-930.
11. Steinherz PG, Gaynon P, Miller DR, et al. Improved disease free survival of children with ALL at high risk for early relapse with the New York regimen: a new intensive therapy protocol. J Clin Oncol. 1986;4:744-752.
12. Gaynon PS, Trigg ME, Heerema NA, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia. 2000;14:2223-2233.
13. Schrappe M, Reiter A, Wolf-Dieter L, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. Blood. 2000;95:3310-3322.